Table S2: Characteristics of Studies Not Providing Individual Patient Data

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study | N\* | N† | N (%) preterm‡ | Active treatment§ | Control treatment | Allocation ratio | BV definition | Gestation at randomization | Sonography for gestational age |
| Duff, 1991 | 108 | 0|| | Not stated | AX, 500 mg tid x 14 d | Matching placebos | Adaptive randomization, biased coin; blocks of 6 | Nugent score 7+ and Amsel | 15-25 weeks | Not stated |
| Morales, 1994 | 94 | 80 | 24 (30%) | MZ, 250 mg tid x 7d | Identical appearing Vitamin C tablet | 1:1 | Amsel criteria | 13-20 weeks | Yes, before randomization |
| Joesoef, 1995 | 745 | 681 | 97 (14%) | Topical CM, 7 evenings | Matching placebo | 1:1, permuted blocks of 6, stratified by study site | Nugent score 7+ and pH>4.5 | 14-26 weeks | Yes, before randomization |
| McDonald 1997 | 490 | 480 | 34 (7%) | MZ, 400 mg bid x 2d, repeated in 4 weeks if BV present | Matching placebo | 1:1, blocks of 16 stratified by study site | Spiegel Gram stain score | 16-26 weeks | Yes, <18 weeks |
| Vermeulen, 1999 | 22 | 22 | 2 (9%), <34 weeks | Topical CM, 7 evenings at 26 and 32 weeks | Matching placebo | 1:1, blocks of 4, stratified by BV status and study site | Nugent score 7+ | <26 weeks | Yes, timing not stated |
| Kekki, 2001 | 375 | 375 | 16 (4%) | Topical CM every evening x 7d | Matching placebo | 1:1, “block randomization within each center” | Spiegel Gram stain score | 10-17 weeks | Yes, timing not stated |
| Guaschino, 2003 | 112 | 100 | 14 (14%) | Topical CM, 7 evenings | No treatment | 1:1, stratified by study site | Nugent score 7+ | 13-20 weeks | Yes, before randomization |
| Giuffrida, 2006 | 60 | 60 | Mean 38.2 weeks | Topical CM ovules, 100 mg x 3d, repeat at 3 weeks if still positive | Hydrogen peroxide cream, 0.5% x 5 d, repeated at 3 weeks if still positive | 1:1 | Unclear | 13-16 weeks | Yes, before randomization |
| Moniri, 2009 | 120 | 120 | 4 (3%) | MZ, 500 mg bid x 7d | Untreated, uninformed of BV | Not stated | Amsel criteria | 20-34 weeks | Not stated |
| Subtil, 2018 | 2869 | 2860 | 200 (7%) | Oral CM, bid x 4 days for 1 or 3 courses 1 month apart | Matching placebo 2, 0 or 3 courses | 1:1:1, blocks of 6, stratified by study site | Nugent score 7+ | <15 weeks | Best obstetric estimate |

\* Number of pregnancies in published paper.

† Number of pregnancies in published paper with BV and outcome data.

‡ Among women with outcome data present in published paper.

§ AX=amoxicillin; MZ=metronidazole; CM=clindamycin.

|| Published results state only that gestational age at birth did not differ significantly between treated and control groups.